Study finds Norgine's Dantrium reduces fatal anesthetic reactions

19 August 2013

A new epidemiologic study has found that Dantrium (dantrolene sodium) is effective in reducing fatal anesthetic reaction in malignant hyperthermia.

The Canadian study revealed that 15.5% of adverse anesthetic reactions are triggered by succinylcholine alone. In line with previous findings, the study also concluded that early recognition and prompt administration of dantrolene intravenous are critical for patient survival and reduction of complications.

Dantrium, commercialized in Europe by privately-owned UK-based pharma company Norgine, is indicated for malignant hyperthermia and acts peripherally to lower the intracellular calcium concentration in the skeletal muscle.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical